Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Phase of Trial: Phase I
Latest Information Update: 09 May 2018
At a glance
- Drugs Eflapegrastim (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Pharmacokinetics
- Sponsors Spectrum Pharmaceuticals
- 30 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 30 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 12 Jul 2017 Status changed from not yet recruiting to recruiting.